Overview
Clinical Meaning
Recurrent C. difficile infection (rCDI) occurs in 20 25% of patients after the first episode and 40 65% after a second episode, driven by failure to restore the protective colon...
WHNP
WHNP
Recurrent C. difficile infection (rCDI) occurs in 20-25% of patients after the first episode and 40-65% after a second episode, driven by failure to restore the protective colonic microbiome. The disrupted gut flora cannot provide colonization resistance, allowing persistent C. difficile spores (which survive standard treatment) to germinate and re-establish toxin-producing infection. Fidaxomicin is a narrow-spectrum macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing C. difficile while preserving the anaerobic gut flora essential for colonization resistance — this microbiome-sparing property reduces recurrence rates by approximately 50% compared to vancomycin. For patients with multiple recurrences, fecal microbiota transplant (FMT) directly restores the diverse colonic microbiome, achieving 80-90% cure rates by re-establishing competitive exclusion of C. difficile.
Unlock full lesson + practice questions
4 more sections with scenarios, priorities, and review drills.
Final rapid review before practice
Next study step
Finish the lesson first, then choose a focused activity to apply what you just reviewed.
Continue studying
Sign in to save progress on this lesson.
Unlock the interactive lesson quiz with a plan that includes this WHNP pathway. You can still explore topic-filtered questions from the bank hubs below.